Qrons Inc. (QRON)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 351.84 Thousand USD | 19.63% |
| 2022 | 294.12 Thousand USD | 35.74% |
| 2021 | 216.68 Thousand USD | 82.65% |
| 2020 | 118.63 Thousand USD | 46.16% |
| 2019 | 81.17 Thousand USD | 224.68% |
| 2018 | 25 Thousand USD | 275.09% |
| 2017 | 6665.00 USD | 86.02% |
| 2016 | 3583.00 USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 381.87 Thousand USD | 6.26% |
| 2024 Q1 | 359.36 Thousand USD | 2.14% |
| 2023 FY | 351.84 Thousand USD | 19.63% |
| 2023 Q4 | 351.84 Thousand USD | 2.12% |
| 2023 Q2 | 337.53 Thousand USD | 10.49% |
| 2023 Q3 | 344.54 Thousand USD | 2.08% |
| 2023 Q1 | 305.49 Thousand USD | 3.87% |
| 2022 Q3 | 280.87 Thousand USD | 4.03% |
| 2022 Q4 | 294.12 Thousand USD | 4.72% |
| 2022 FY | 294.12 Thousand USD | 35.74% |
| 2022 Q1 | 245.97 Thousand USD | 13.52% |
| 2022 Q2 | 270 Thousand USD | 9.77% |
| 2021 Q3 | 178.9 Thousand USD | 26.77% |
| 2021 Q2 | 141.12 Thousand USD | 10.71% |
| 2021 Q1 | 127.46 Thousand USD | 7.45% |
| 2021 FY | 216.68 Thousand USD | 82.65% |
| 2021 Q4 | 216.68 Thousand USD | 21.12% |
| 2020 Q3 | 109.6 Thousand USD | 8.98% |
| 2020 Q4 | 118.63 Thousand USD | 8.24% |
| 2020 FY | 118.63 Thousand USD | 46.16% |
| 2020 Q1 | 91.64 Thousand USD | 12.9% |
| 2020 Q2 | 100.57 Thousand USD | 9.75% |
| 2019 Q1 | 25 Thousand USD | 0.0% |
| 2019 FY | 81.17 Thousand USD | 224.68% |
| 2019 Q4 | 81.17 Thousand USD | 8.23% |
| 2019 Q3 | 75 Thousand USD | 0.0% |
| 2019 Q2 | 75 Thousand USD | 200.0% |
| 2018 Q4 | 25 Thousand USD | 0.0% |
| 2018 FY | 25 Thousand USD | 275.09% |
| 2018 Q1 | 13.02 Thousand USD | 95.45% |
| 2018 Q2 | 19.45 Thousand USD | 49.37% |
| 2018 Q3 | 25 Thousand USD | 28.48% |
| 2017 Q2 | 8611.00 USD | 41.56% |
| 2017 FY | 6665.00 USD | 86.02% |
| 2017 Q3 | 182.00 USD | -97.89% |
| 2017 Q4 | 6665.00 USD | 3562.09% |
| 2017 Q1 | 6083.00 USD | 69.77% |
| 2016 Q4 | 3583.00 USD | 0.0% |
| 2016 FY | 3583.00 USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.146% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 91.464% |
| SQZ Biotechnologies Company | 27.47 Million USD | 98.719% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.189% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 98.818% |
| Mesoblast Limited | 118.7 Million USD | 99.704% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 62.896% |
| Genus plc | 233.1 Million USD | 99.849% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 87.993% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 73.813% |
| Marizyme, Inc. | 18.71 Million USD | 98.12% |
| ContraFect Corporation | 2.88 Million USD | 87.787% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 53.087% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -159.691% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 75.673% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 84.873% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 93.782% |
| MultiCell Technologies, Inc. | 202.58 USD | -173582.989% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.388% |
| EV Biologics, Inc. | 1.49 Million USD | 76.461% |
| Q BioMed Inc. | 4.1 Million USD | 91.439% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 98.937% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 44.158% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 71.356% |
| Biomind Labs Inc. | 735.54 Thousand USD | 52.165% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.795% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 97.293% |
| Skye Bioscience, Inc. | 4.61 Million USD | 92.376% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 60.38% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -148.623% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 94.007% |
| IMV Inc. | 28.88 Million USD | 98.782% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -1268.043% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 84.42% |
| GB Sciences, Inc. | 1.75 Million USD | 80.001% |
| Alpha Cognition Inc. | 1.22 Million USD | 71.169% |
| HST Global, Inc. | 98.31 Thousand USD | -257.863% |
| CSL Limited | 12.18 Billion USD | 99.997% |
| Halberd Corporation | 150 Thousand USD | -134.565% |
| Enzolytics Inc. | 996.33 Thousand USD | 64.686% |
| Resverlogix Corp. | 6.49 Million USD | 94.579% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 26.315% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -37.66% |
| argenx SE | 20 Million USD | 98.241% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.228% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 87.01% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -3341.046% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.916% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -75.383% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 85.326% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -53.45% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.48% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 88.373% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 2.186% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.269% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -136.689% |
| BioStem Technologies, Inc. | 4.71 Million USD | 92.532% |
| ONE Bio Corp. | 19.71 Million USD | 98.215% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -40.636% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -41.463% |
| Agentix Corp. | 50 Thousand USD | -603.694% |
| LadRx Corporation | 33.6 Thousand USD | -946.977% |
| Cell Source, Inc. | 9.25 Million USD | 96.198% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 53.472% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 53.472% |
| NovAccess Global Inc. | 2.19 Million USD | 84.006% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 95.025% |
| Itoco Inc. | 228.37 Thousand USD | -54.064% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -66.772% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 92.939% |
| Kadimastem Ltd | 891.22 Thousand USD | 60.521% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 12.443% |
| CytoDyn Inc. | 30.07 Million USD | 98.83% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 27.347% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 95.501% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -187.222% |
| Rebus Holdings, Inc. | 310 Thousand USD | -13.499% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 92.57% |
| International Stem Cell Corporation | 4.17 Million USD | 91.579% |
| Bioxytran, Inc. | 1.92 Million USD | 81.722% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -463.74% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 83.867% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 95.769% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 95.902% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 77.38% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -31.286% |
| Neutra Corp. | 54.15 Thousand USD | -549.692% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 80.773% |
| PureTech Health plc | 25.51 Million USD | 98.621% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 71.26% |
| IXICO plc | 472.02 Thousand USD | 25.46% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 97.73% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.435% |
| CSL Limited | 12.18 Billion USD | 99.997% |
| Cellectis S.A. | 92.77 Million USD | 99.621% |